2022ASCOGU|盛锡楠教授:尿路上皮癌HER2相关研究进展
HER2改变与尿路上皮癌的临床病程和预后
参考文献 1. Michael Lattanzi, Andrew Niederhausern, Junting Zheng,et al. Incidence and clinical outcomes of HER2-altered bladder cancer (BC) patients (pts)[J]. J Clin Oncol 40, 2022 (suppl 6; abstr 556). 2. Carissa Ellen Chu, Manuel De Jesus Escano, Wesley Yip,et al.Human epidermal growth factor receptor 2 (HER2) and fibroblast growth factor receptor 3 (FGFR3) mutations to reveal biological pathways in urothelial carcinoma[J]. J Clin Oncol 40, 2022 (suppl 6; abstr 567). 3. Siming Li, Xiaowen Wu, Xieqiao Yan,et al.Prognostic value of HER2 expression levels for upper tract urothelial carcinoma[J]. J Clin Oncol 40, 2022 (suppl 6; abstr 557). 4. Siming Li, Xiaowen Wu, Xieqiao Yan,et al. Impact of different HER2 expression levels on the outcomes of second-line immunotherapy for metastatic urothelial carcinoma[J]. J Clin Oncol 40, 2022 (suppl 6; abstr 524). 5. Li Zhou, Huayan Xu, Siming Li,et al. Li Zhou, Huayan Xu, Siming LiStudy RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma[J]. J Clin Oncol 40, 2022 (suppl 6; abstr 515). 6.Matt D. Galsky, Gianluca Del Conte, Silvia Foti,et al. Primary analysis from DS8201-A-U105: A phase 1b, 2-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC)[J]. J Clin Oncol 40, 2022 (suppl 6; abstr 438).